DYRK1A and Dravet syndrome: Increased dosages of single genes in Hsa21, such as Dyrk1A, have been proposed to account for many of the alterations in neural development and abnormal phenotypes associated with DS and are thus targets for therapy development (Duchon and Herault, 2016).